Halozyme Therapeutics, Inc. (NASDAQ:HALO) CFO Nicole Labrosse Sells 10,000 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CFO Nicole Labrosse sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $51.93, for a total value of $519,300.00. Following the transaction, the chief financial officer now owns 15,480 shares in the company, valued at $803,876.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Halozyme Therapeutics Stock Up 1.4 %

NASDAQ HALO opened at $52.36 on Friday. The company has a market capitalization of $6.66 billion, a price-to-earnings ratio of 21.64, a PEG ratio of 0.52 and a beta of 1.28. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44. Halozyme Therapeutics, Inc. has a 1-year low of $32.83 and a 1-year high of $53.00. The stock’s 50 day moving average is $45.31 and its two-hundred day moving average is $40.46.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.64 by $0.07. The business had revenue of $195.88 million for the quarter, compared to the consensus estimate of $201.72 million. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. Equities analysts forecast that Halozyme Therapeutics, Inc. will post 3.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of HALO. TD Asset Management Inc boosted its holdings in shares of Halozyme Therapeutics by 517.0% in the 4th quarter. TD Asset Management Inc now owns 1,983,916 shares of the biopharmaceutical company’s stock worth $73,326,000 after acquiring an additional 1,662,390 shares in the last quarter. Norges Bank acquired a new position in shares of Halozyme Therapeutics in the 4th quarter worth approximately $44,935,000. Epoch Investment Partners Inc. lifted its holdings in Halozyme Therapeutics by 250.5% during the 4th quarter. Epoch Investment Partners Inc. now owns 1,163,033 shares of the biopharmaceutical company’s stock worth $42,986,000 after buying an additional 831,199 shares in the last quarter. Boston Partners lifted its holdings in Halozyme Therapeutics by 562.2% during the 4th quarter. Boston Partners now owns 552,392 shares of the biopharmaceutical company’s stock worth $20,218,000 after buying an additional 468,977 shares in the last quarter. Finally, LSV Asset Management acquired a new position in Halozyme Therapeutics during the 4th quarter worth $17,090,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Piper Sandler lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price target for the company from $48.00 to $51.00 in a research note on Friday, June 7th. Wells Fargo & Company boosted their price target on Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a research note on Friday, June 7th. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price objective on shares of Halozyme Therapeutics in a report on Monday, June 24th. JMP Securities decreased their price objective on Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 8th. Finally, Benchmark lifted their price objective on Halozyme Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $57.25.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.